Nutra Pharma Corp.
NPHC
$0.00
$0.000.00%
OTC PK
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -9.86% | 37.97% | 51.86% | -10.07% | -21.67% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -9.86% | 37.97% | 51.86% | -10.07% | -21.67% |
| Cost of Revenue | -12.11% | 38.39% | 12.27% | -15.70% | 56.45% |
| Gross Profit | -8.63% | 37.96% | 94.03% | -7.58% | -38.52% |
| SG&A Expenses | 64.72% | 33.50% | 26.54% | 13.46% | -9.01% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 54.59% | 33.99% | 25.05% | 9.08% | -3.73% |
| Operating Income | -92.69% | -32.35% | -18.46% | -27.60% | -11.46% |
| Income Before Tax | -100.81% | 200.68% | -229.09% | 5.02% | 6.39% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -100.81% | 200.68% | -229.09% | 5.02% | 6.39% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -100.81% | 200.68% | -229.09% | 5.02% | 6.39% |
| EBIT | -92.69% | -32.35% | -18.46% | -27.60% | -11.46% |
| EBITDA | -93.17% | -32.08% | -18.51% | -27.89% | -14.10% |
| EPS Basic | -- | -- | -100.00% | -- | -- |
| Normalized Basic EPS | -- | -- | -- | -- | -- |
| EPS Diluted | -- | -- | -100.00% | -- | -- |
| Normalized Diluted EPS | -- | -- | -- | -- | -- |
| Average Basic Shares Outstanding | 2.08% | 1.12% | 0.44% | 1.50% | 0.57% |
| Average Diluted Shares Outstanding | 2.08% | 392.72% | 0.44% | 1.50% | 0.57% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |